HealthDay News — Hypertension is the most common chronic condition among adults aged 85 years and older, with prevalence higher among women than men, according to a report published in the June Health ...

Sustained reduction seen in body weight versus placebo for adults aged 18 to 75 with overweight or obesity, without diabetes ...

Lower risks for anxiety disorders, substance use disorders, cognitive deficits seen for those undergoing metabolic and bariatric surgery ...

Direct access to Wegovy® (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership ...

A single dose of a synthetic, proprietary formulation of psilocybin (COMP360) was found to improve symptoms in patients with treatment-resistant ...

Topline results were announced from a phase 3 study evaluating sotatercept-csrk in recently diagnosed adults with pulmonary arterial hypertension (PAH).

Topline data were announced from a phase 3 trial evaluating zanzalintinib in combination with atezolizumab in patients with previously treated non-microsatellite instability (MSI)-high metastatic ...

Decision-making was influenced by patient values and did not vary by stage, race and ethnicity, or demographics ...

Incidence rates of composite of death, MI, stroke were lower, but not significantly so, for patients treated with semaglutide ...

HealthDay News — Cannabis use is associated with major adverse cardiovascular events (MACE), according to a systematic review based on real-world data published online June 17 in Heart.

The Food and Drug Administration (FDA) has approved Monjuvi ® (tafasitamab-cxix), in combination with lenalidomide and rituximab, for the treatment of adult patients with relapsed or refractory (R/R) ...

Through August 16, 2024, the Agency has identified 13 cases worldwide of hyperthermia associated with scopolamine patches.